Cycloset Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions

There is currently no warning information available for this product. We apologize for any inconvenience.

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.


1.1 Type 2 diabetes mellitus

CYCLOSET is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

1.2 Important Limitations of Use
  • CYCLOSET should not be used to treat type 1 diabetes or diabetic ketoacidosis.
  • Limited efficacy data in combination with thiazolidinediones
  • Efficacy has not been confirmed in combination with insulin.


There is currently no drug history available for this drug.

Other Information

CYCLOSET Tablets contain bromocriptine mesylate, a dopamine receptor agonist. Bromocriptine mesylate is chemically designated [Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, monomethanesulfonate (salt), (5'α)-]. CYCLOSET is a single enantiomer with absolute configuration 5R, 8R, 2'R, 5'S, 11'S, 12'S.

The structural formula of bromocriptine is shown below:

Molecular Formula

Bromocriptine mesylate is a white or slightly colored fine crystalline powder with a molecular formula of C32H40BrN5O5∙CH4SO3 and a molecular weight of 750.72. CYCLOSET tablets contain bromocriptine mesylate USP in an amount equivalent to 0.8 of bromocriptine. Each tablet contains the following inactive ingredients: lactose, corn starch, magnesium stearate, colloidal silicon dioxide, and citric acid.

Cycloset Manufacturers

  • Santarus, Inc.
    Cycloset (Bromocriptine Mesylate) Tablet [Santarus, Inc.]

Login To Your Free Account